Biostage (Nasdaq: BSTG) is a compelling investment
Biostage (Nasdaq: BSTG) is a compelling investment opportunity in regenerative medicine - they have been successful in using stem cells and a scaffold to create organ implants for tubular organs. Best success in regenerating the esophagus in a large animal study with Mayo Clinic.
Plan is to file with FDA by year end 2016 seeking OK to start human clinical trials in 2017. Have also filed for orphan designation for esophageal implant project. $18M market cap currently.
[url=htpp://www.biostage.com]Biostage Website[/url]
2
Biostage, Inc. (BSTG) Stock Research Links
Posts that I make on Investors Hangout reflect my own personal thinking and opinion and are neither endorsed nor approved by the subject companies, many of which may be clients or client prospects of our our NY-based investor relations consulting firm.
David Collins, Managing Director
Catalyst Global Investor Relations
www.catalyst-ir.com
dcc@catatalyst-ir.com
212 924 9800
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Jushi Holdings Inc. to Announce Financial Results BOCA RATON, Fla. -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a well-established player in the cannabis industry, is gearing up to share its financial performance for the second quarter. This key announcement will take place after market hours on the fifth day of August. Details for...
Continue Reading
Mike Tyson's Exciting Role with BoltBetz BoltBetz, known for revolutionizing cashless gaming technology, has recently announced a significant partnership with the legendary boxing champion Mike Tyson. With Tyson as both a strategic investor and promotional partner, this collaboration promises to transform the landscape of gaming across various casinos. Tyson's entry into...
Continue Reading
Portage Community Bank Appoints New Executive Leader Portage Community Bank is thrilled to announce the appointment of C. Joseph Assid as the new Executive Vice President and Chief Financial Officer. With a rich experience spanning over twenty-five years in financial institution accounting, audit, and assurance services, Mr. Assid brings invaluable expertise to this...
Continue Reading
Angelalign Technology Inc., listed as 6699.HK on the Hong Kong Stock Exchange, is heading back to court—this time, challenging a ruling from the Jinan Intermediate People's Court in China. They aim to overturn a judgment that ordered their subsidiaries to stop using key systems like the masterForce biomechanics simulation and the ATreat digital diagnosis system for...
Continue Reading
Unicycive Therapeutics Investigated for Potential Claims Investors holding securities in Unicycive Therapeutics, Inc. are facing an important deadline for potential legal actions. The company, listed on NASDAQ as UNCY, has come under scrutiny, and it's essential for affected investors to understand their options moving forward. Who Should Be Concerned? If you acquired...
Continue Reading